Table 3.
Outcome of treatment
Before CTL evaluation
|
Fold reduction in EBV load
|
Outcome at 1 y
|
||||||
---|---|---|---|---|---|---|---|---|
Patient | EBV DNA load | PTLD | CTL dose | Toxicity | 2 mo after | 6 mo after | Clinical | EBV DNA load |
1 | 4 156 | No | 2 × 107/m2 | No | 2.3 | 0.7 | Well | 1 500 |
2 | 136 000 | No | 2 × 107/m2 | No | 0.6 | 3 | Well | 180 000 |
3 | 4 506 | No | 2 × 107/m2 | Transient rise in AST* | 2.5 | 3.7 | Well | 400 |
4 | 16 204 | No | 5 × 107/m2 | No | 0.1 | 1 | Well | 15 000 |
5 | 10 172 | No | 5 × 107/m2 | No | 0.4 | 1.3 | Well | 3 900 |
6 | 6 704 | No | 5 × 107/m2 | No | 0.6 | 10 | Well | 1 100 |
7 | 4 938 | No | 1 × 108/m2 | No | 0.9 | 0.6 | Well | 3 900 |
8 | 14 002 | No | 1 × 108/m2 | No | 0.6 | 0.9 | Well | 7 200 |
9 | 2 500 | No | 5 × 107/m2 × 3 | No | 1.7 | 10 | Well | 7 000 |
10 | 1 100 | No | 5 × 107/m2 × 3 | No | 2.7 | 10 | Well | < 400 |
11 | 1 500 | No | 5 × 107/m2 × 4 | No | 0.4 | 1.2 | Well | 700 |
12 | 20 900 | Eye | 5 × 107/m2 × 4 | No | 0.8 | 3 | Well† | 25 000 |
Two months after CTL infusion.
PTLD decrease in size.